GYRE (Gyre Therapeutics) Current Deferred Revenue: $0.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $5.75
GF Value $9.77
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Current Deferred Revenue?

Gyre Therapeutics GYRE -1.03% 39 Current Deferred Revenue is $0.1 Mil as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.77 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Gyre Therapeutics's current deferred revenue for the quarter that ended in Mar. 2026 was $0.1 Mil.

Gyre Therapeutics Current Deferred Revenue Related Terms

Gyre Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Current Deferred Revenue Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.17 0.08 0.16 0.11

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.15 0.11 0.10
GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.1 Mil mean?
Gyre Therapeutics (GYRE) has a Current Deferred Revenue of $0.1 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Current Deferred Revenue too high?
Gyre Therapeutics' current Current Deferred Revenue is $0.1 Mil. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Current Deferred Revenue compare to OCS and RIGL?
Gyre Therapeutics' Current Deferred Revenue of $0.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Current Deferred Revenue is $0.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.77, compared to a current price of $5.75 — trading 41.1% below its estimated fair value. The current Current Deferred Revenue is $0.1 Mil. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Current Deferred Revenue is $0.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $5.75 is trading 41.1% below its estimated GF Value™ of $9.77. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Current Deferred Revenue: $0.1 Mil
  • GF Value™: $9.77 vs. price of $5.75 (41.1% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.75
Price
$9.77
GF Value